The impact of pricing strategy on the costs of oral anti‐cancer drugs
Open Access
- 27 May 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (8) , 3770-3781
Abstract
Background: The soaring costs of anti‐cancer drugs pose a threat to the sustainability of cancer care. The pricing strategy chosen by manufacturers can impact the costs of oral anti‐cancer drugs during dose modifications, but this issue remains under‐recognized in the literature. In general, with the flat pricing strategy, there is a single fixed price for each tablet regardless of dosage strength, whereas with linear pricing, the price of each tablet increases with its dose. We hypothesize that flat pricing will have increased drug costs compared to linear pricing during dose reductions since the cost remains fixed despite decreased dose requirements. This practice may have significant financial implications considering the high costs, extensive utilization, and frequent occurence of dose reductions with anti‐cancer drugs. Methods: Oral anti‐cancer drugs reviewed by the pan‐Canadian Oncology Drug Review program between 2011 and 2018 were identified. The cost per mg and cost per 28‐day cycle were calculated for dose levels −2 to +2. The percent change in cost per mg and cost per cycle during dose modifications from the standard dose were calculated. We conducted Mann‐Whitney U and Fisher‐exact tests to compare the association between drug costs during dose reductions and pricing strategy.Results: In this study, 30 oral anti‐cancer drugs for use in 41 indications were analyzed; 44% of drugs used linear pricing and 56% used flat pricing. Dose reductions increased the mean cost per mg for drugs with linear pricing by 14.7% (range: 0%‐50%) at dose level −1 and 17.2% (range: 0%‐50%) at dose level −2 and flat pricing by 60.8% (range: 19%‐100%) at dose level −1 and 99.1% (range: 0%‐300%) at dose level −2. The cost per mg was significantly increased in drugs using flat pricing compared to linear pricing when dose reduction to either level ‐1 (P = 0.010) or level ‐2 (P = 0.006) occurred. The mean cost per cycle was decreased for drugs using linear pricing by 20.9% (range: −40% to 0%) at dose level −1 and 48.7% (range: −60% to −25%) at dose level −2 and flat pricing by 0.8% (range −6% to 0%) at dose level −1 and 11.0% (range: −50% to 100%) at dose level −2. The cost per cycle was significantly decreased in drugs with linear pricing compared to flat pricing when the standard dose is reduced to either dose level ‐1 (P = 0.005) or dose level ‐2 (P = 0.026).Conclusions: Overall, flat pricing had significantly greater costs compared to linear pricing during dose reductions of anti‐cancer drugs. While there is a general expectation that the cost of drugs should decrease with dose reduction, drugs with flat pricing were generally found to have increased cost per mg and no change in the cost per cycle. The resultant increased spending on drug acquisition (despite purchasing lower doses) lead to financial wastage, which has significant implications on cost‐effectiveness considerations and budgets. Future economic evaluations should take into consideration the hidden costs associated with dose reductions of flat priced drugs.Keywords
This publication has 22 references indexed in Scilit:
- The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatmentCA: A Cancer Journal for Clinicians, 2018
- The economic burden of cancer care in Canada: a population-based cost studyCMAJ Open, 2018
- Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare BeneficiariesJournal of Clinical Oncology, 2017
- The high price of anticancer drugs: origins, implications, barriers, solutionsNature Reviews Clinical Oncology, 2017
- Rising Cost of Cancer Pharmaceuticals: Cost Issues and Interventions to Control CostsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive PressureHealth Affairs, 2016
- Financial Insolvency as a Risk Factor for Early Mortality Among Patients With CancerJournal of Clinical Oncology, 2016
- Five Years of Cancer Drug ApprovalsJAMA Oncology, 2015
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- Projections of the Cost of Cancer Care in the United States: 2010-2020JNCI: Journal of the National Cancer Institute, 2011